{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+Saline+Injection&page=2", "query": { "intervention": "Normal Saline Injection", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+Saline+Injection&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-18T05:58:22.485Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04387461", "title": "Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Muscle Invasive Bladder Cancer" ], "interventions": [ { "name": "CG0070", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab Injection", "type": "BIOLOGICAL" }, { "name": "n-dodecyl-B-D-maltoside", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "CG Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2020-12-08", "completion_date": "2024-05-28", "has_results": false, "last_update_posted_date": "2024-09-25", "last_synced_at": "2026-09-18T05:58:22.485Z", "location_count": 13, "location_summary": "La Jolla, California • Orange, California • Tampa, Florida + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04387461" }, { "nct_id": "NCT03885596", "title": "Open-Label CA-008 (Vocacapsaicin) in Bunionectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pain" ], "interventions": [ { "name": "CA-008", "type": "DRUG" }, { "name": "Ketorolac", "type": "DRUG" }, { "name": "Acetaminophen IV", "type": "DRUG" }, { "name": "Fentanyl", "type": "DRUG" }, { "name": "Bupivacaine Hydrochloride", "type": "DRUG" }, { "name": "Lidocaine HCl", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Acetaminophen Oral", "type": "DRUG" }, { "name": "Lidocaine Hydrochloride", "type": "DRUG" }, { "name": "Exparel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Concentric Analgesics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 36, "start_date": "2019-03-25", "completion_date": "2019-10-22", "has_results": true, "last_update_posted_date": "2021-10-27", "last_synced_at": "2026-09-18T05:58:22.485Z", "location_count": 1, "location_summary": "Pasadena, California", "locations": [ { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03885596" }, { "nct_id": "NCT02713490", "title": "Local Infiltration Analgesia With and Without EXPAREL Following Total Knee Arthroplasty", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pain" ], "interventions": [ { "name": "EXPAREL", "type": "DRUG" }, { "name": "Bupivacaine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pacira Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 140, "start_date": "2016-04-18", "completion_date": "2017-02-08", "has_results": true, "last_update_posted_date": "2020-12-11", "last_synced_at": "2026-09-18T05:58:22.485Z", "location_count": 17, "location_summary": "Fremont, California • Loma Linda, California • Fort Lauderdale, Florida + 13 more", "locations": [ { "city": "Fremont", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Weston", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02713490" }, { "nct_id": "NCT01664559", "title": "Pain Control for Intrauterine Device Placement: A Trial of Ketorolac Prior to Intrauterine Device Placement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pain Control With IUD Insertion" ], "interventions": [ { "name": "Ketorolac", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lynn Ngo", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 67, "start_date": "2012-07", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2015-12-23", "last_synced_at": "2026-09-18T05:58:22.485Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01664559" }, { "nct_id": "NCT05717062", "title": "Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Snakebite", "Envenoming, Snake" ], "interventions": [ { "name": "Varespladib intravenous form", "type": "DRUG" }, { "name": "varespladib-methyl- oral form", "type": "DRUG" }, { "name": "Placebo intravenous form", "type": "DRUG" }, { "name": "Placebo - oral form", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ophirex, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2023-05-30", "completion_date": "2025-02-24", "has_results": false, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-09-18T05:58:22.485Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Palm Springs", "state": "California" }, { "city": "Rosamond", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05717062" }, { "nct_id": "NCT07472491", "title": "A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Known or Highly Suspected Central Nervous System (CNS) Lesion", "Known or Highly Suspected Body (Excluding CNS) Lesion" ], "interventions": [ { "name": "Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL", "type": "DRUG" }, { "name": "MRI Scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Gadobutrol", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "GE Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 640, "start_date": "2026-04-01", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-09-18T05:58:22.485Z", "location_count": 2, "location_summary": "Rochester, Minnesota • The Woodlands, Texas", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07472491" }, { "nct_id": "NCT03525678", "title": "A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin frozen liquid", "type": "DRUG" }, { "name": "Belantamab mafodotin lyophilized powder", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2018-06-18", "completion_date": "2024-09-12", "has_results": true, "last_update_posted_date": "2025-09-03", "last_synced_at": "2026-09-18T05:58:22.485Z", "location_count": 21, "location_summary": "New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 15 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03525678" }, { "nct_id": "NCT01147341", "title": "Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Cimzia", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael Schiff, MD", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 37, "start_date": "2010-07", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-09-18T05:58:22.485Z", "location_count": 12, "location_summary": "Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147341" }, { "nct_id": "NCT04852172", "title": "L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Vaso Occlusive Crisis (VOC)" ], "interventions": [ { "name": "L-citrulline", "type": "DRUG" }, { "name": "D5 1/2NS", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Asklepion Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Years to 21 Years" }, "enrollment_count": 30, "start_date": "2021-04-29", "completion_date": "2024-02-29", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-18T05:58:22.485Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Jackson, Mississippi", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jackson", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT04852172" }, { "nct_id": "NCT02610296", "title": "QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Delayed Graft Function" ], "interventions": [ { "name": "QPI-1002", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Quark Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 594, "start_date": "2016-03-01", "completion_date": "2019-01-08", "has_results": false, "last_update_posted_date": "2020-05-13", "last_synced_at": "2026-09-18T05:58:22.485Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02610296" } ] }